Subscribe to Newsletter

Integrated workflow for rapid selection and optimization of hybridoma cell lines

Hybridomas are comprised of the fusion between B-cell splenocytes from antigen-immunized mice and a myeloma tumor cell line result in immortalized antibody-producing clonal cell lines that can be screened for antigen-specific binding. Today, more than half of the commercialized antibody drugs are from hybridoma cell lines, and hybrid hybridomas have been used to produce bispecific monoclonal antibodies. Screening a hybridoma fusion and then subcloning candidate hybrids are time-consuming elements of the monoclonal antibody discovery process (Figure 1).

Read the full article now

Log in or register to read this article in full and gain access to The Medicine Maker’s entire content archive. It’s FREE!

Receive content, products, events as well as relevant industry updates from The Medicine Maker and its sponsors.
Stay up to date with our other newsletters and sponsors information, tailored specifically to the fields you are interested in

When you click “Subscribe” we will email you a link, which you must click to verify the email address above and activate your subscription. If you do not receive this email, please contact us at [email protected].
If you wish to unsubscribe, you can update your preferences at any point.

Register to The Medicine Maker

Register to access our FREE online portfolio, request the magazine in print and manage your preferences.

You will benefit from:
  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts
  • Receive print (and PDF) copies of The Medicine Maker magazine